Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1948 1
1957 1
1975 13
1976 9
1977 1
1978 4
1979 6
1980 2
1981 7
1982 4
1983 5
1984 7
1985 10
1986 9
1987 21
1988 17
1989 7
1990 14
1991 12
1992 10
1993 14
1994 10
1995 4
1996 9
1997 9
1998 7
1999 3
2000 4
2001 4
2002 5
2003 1
2004 3
2005 6
2006 4
2007 3
2008 4
2009 3
2010 8
2011 2
2012 9
2013 7
2014 11
2015 13
2016 14
2017 20
2018 8
2019 4
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

333 results
Results by year
Filters applied: . Clear all
Page 1
Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension.
Biaggioni I, et al. BMC Neurol 2017 - Clinical Trial. PMID 28494751 Free PMC article.
Droxidopa was effective in patients using inhibitors of dopa decarboxylase (DDCI; the enzyme that converts droxidopa to norepinephrine), but its efficacy was numerically greater in non-DDCI users. Droxidopa was well-tolerated. Rates of most adverse events were similar between groups. Supine hypertension rates were low, but slightly higher in patients receiving droxidopa (≤7.9% vs ≤4.6% for placebo); patients with severe hypertension at screening were excluded from these studies. ...
Droxidopa was effective in patients using inhibitors of dopa decarboxylase (DDCI; the enzyme that converts droxidopa to norepi
Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension.
Palma JA, et al. Neurology 2018 - Clinical Trial. PMID 30232253 Free PMC article.
CONCLUSIONS: In patients with nOH, lower supine resting plasma NE levels are associated with a greater pressor effect of droxidopa treatment. This finding should help identify patients with nOH most likely to respond to standard doses of droxidopa. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that lower supine plasma NE levels accurately identify patients with nOH more likely to have a greater pressor effect from droxidopa....
CONCLUSIONS: In patients with nOH, lower supine resting plasma NE levels are associated with a greater pressor effect of droxidopa tr …
Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials.
Chen JJ, et al. Ann Pharmacother 2018. PMID 29972032
Comparative analysis revealed a significant credible difference between droxidopa and midodrine. The RR for supine hypertension was significantly greater for midodrine, but not droxidopa, when compared with placebo (droxidopa RR = 1.4 [95% CrI = 0.7-2.7] and midodrine RR = 5.1 [95% CrI = 1.6-24]). ...However, midodrine, but not droxidopa, significantly increases risk of supine hypertension....
Comparative analysis revealed a significant credible difference between droxidopa and midodrine. The RR for supine hypertension was s …
Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
Kaufmann H, et al. Neurology 2014 - Clinical Trial. PMID 24944260 Free PMC article.
At endpoint, supine systolic BP >180 mm Hg was observed in 4.9% of droxidopa and 2.5% of placebo recipients. Adverse events reported in ≥ 3% of double-blind droxidopa recipients were headache (7.4%) and dizziness (3.7%). ...CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that in patients with symptomatic nOH who respond to open-label droxidopa, droxidopa improves subjective and objective manifestation of nOH at 7 days....
At endpoint, supine systolic BP >180 mm Hg was observed in 4.9% of droxidopa and 2.5% of placebo recipients. Adverse events report …
The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats.
Rodríguez S, et al. Liver Int 2015. PMID 24517276
BACKGROUND & AIMS: Droxidopa improves hemodynamic and renal alterations of cirrhotic rats without changing portal pressure. We aimed to evaluate the effects of a combined treatment with droxidopa and non-selective beta-blockers or statins in order to decrease portal pressure, while maintaining droxidopa beneficial effects. ...Atorvastatin + droxidopa combination also failed to reduce PP, but maintained the beneficial increase in MAP and superior mesenteric artery resistance (SMAR) and decrease in blood flow (SMABF) caused by droxidopa. ...
BACKGROUND & AIMS: Droxidopa improves hemodynamic and renal alterations of cirrhotic rats without changing portal pressure. We ai …
Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases.
Pérez-Lloret S, et al. Expert Opin Pharmacother 2019 - Review. PMID 30730771
Areas covered: The authors review the effects of droxidopa in NOH with a focus on the neurodegenerative diseases PD, MSA, and pure autonomic failure (PAF). ...The FDA granted droxidopa approval in the frame of an 'accelerated approval program' provided further studies are conducted to assess its long-term effects on OH symptoms....
Areas covered: The authors review the effects of droxidopa in NOH with a focus on the neurodegenerative diseases PD, MSA, and pure au …
Orthostatic hypotension for the cardiologist
Mar PL and Raj SR. Curr Opin Cardiol 2018 - Review. PMID 28984649 Free PMC article.
Finally, the United States Food and Drug Administration (FDA) recently approved droxidopa, a synthetic oral norepinephrine prodrug, in 2014 for the treatment of neurogenic orthostatic hypotension (nOH), and it represents a well tolerated, effective, and easy to use intervention for nOH. ...
Finally, the United States Food and Drug Administration (FDA) recently approved droxidopa, a synthetic oral norepinephrine prodrug, i …
Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects.
Chen JJ and Hewitt LA. Drugs R D 2018 - Clinical Trial. PMID 29392574 Free PMC article.
BACKGROUND: Droxidopa is an oral prodrug of norepinephrine approved for the treatment of symptomatic neurogenic orthostatic hypotension. ...CONCLUSIONS: Absorption of a single dose of droxidopa is slowed after a high-fat/high-calorie meal; for consistent effect, administer droxidopa in the same manner (with or without food). ...
BACKGROUND: Droxidopa is an oral prodrug of norepinephrine approved for the treatment of symptomatic neurogenic orthostatic hypotensi …
333 results
Jump to page
Feedback